EMEA-000901-PIP04-17-M02
Key facts
Invented name |
Jakavi
|
Active substance |
Ruxolitinib (phosphate)
|
Therapeutic area |
Oncology
|
Decision number |
P/0527/2021
|
PIP number |
EMEA-000901-PIP04-17-M02
|
Pharmaceutical form(s) |
|
Condition(s) / indication(s) |
Treatment of chronic Graft versus Host Disease (cGvHD)
|
Route(s) of administration |
|
Contact for public enquiries |
Novartis Europharm Limited
Tel. +41 6132 41111 |
Decision type |
PM: decision on the application for modification of an agreed PIP
|